Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder

<p>12-CK Score from RNA Sequencing</p>

Guardado en:

Detalles Bibliográficos
Autor principal:	Roger Li (17078665) (author)
Otros Autores:	Wade J. Sexton (17078668) (author), Jasreman Dhillon (15212961) (author), Anders Berglund (14954401) (author), Shreyas Naidu (17078671) (author), Gustavo Borjas (17078674) (author), Kyle Rose (17078677) (author), Youngchul Kim (9092151) (author), Xuefeng Wang (14955103) (author), Jose R. Conejo-Garcia (14955115) (author), Rohit K. Jain (17078680) (author), Michael A. Poch (17078683) (author), Philippe E. Spiess (17078686) (author), Julio Pow-Sang (17078689) (author), Scott M. Gilbert (17078692) (author), Jingsong Zhang (15037632) (author)
Publicado:	2025
Materias:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Genitourinary Cancers Bladder cancer Immunotherapy Checkpoint blockade
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares